79 results about "Melanocyte" patented technology

Provided are a whitening and freckle-removing composition, a gel, a preparation method therefor, and a use thereof, relating to the technical field of skin-care products. The whitening and freckle-removing composition comprises tranexamic acid, nicotinamide, 4-butylresorcinol, licorice extract, 3-o-ethyl ascorbic acid, and glutathione. For the whitening composition, by inhibiting the activity of tyrosinase, blocking the transfer of melanin from melanocytes to keratinocytes, and inhibiting the formation and accumulation of melanin by means of multiple mechanisms including oxidation resistance, and by means of the synergistic action of all components, cosmetic benefits of whitening and freckle-removing are achieved. The whitening and freckle-removing gel has a simple preparation method, has a mild and non-sensitizing formula, is safe and non-irritating, and is suitable for large-scale production and application.

The invention provides a tyrosinase inhibitor compound as shown in a formula (I), a composition as well as a preparation method and application of the tyrosinase inhibitor compound. The compound not only has excellent tyrosinase inhibitory activity, but also has good physicochemical properties, can meet the use requirements of people at an extremely low concentration, and has no toxicity to melanocytes or skin.

The application provides a tyrosinase-based transdermal delivery system for treating vitiligo, which is a core-shell structure, the core is tyrosinase, and the shell is a polymer shell layer. The application coats a polymer protective layer on the surface of the tyrosinase through in-situ polymerization reaction on the double bond of the tyrosinase, can effectively protect the activity of the tyrosinase and promote the transdermal delivery of the tyrosinase, and can control the targeted delivery of the tyrosinase nanogel to melanocytes in the deep part of the skin and hair follicle by adjusting the polymerization conditions of the polymer shell, so as to promote the in-situ synthesis of melanin. The transdermal delivery system of the application can also load active small molecules with anti-inflammatory function in the center of the tyrosinase, and the small molecules are released after being targeted and delivered to the inflammation area of vitiligo along with the tyrosinase nanogel, so as to relieve inflammation and protect melanocytes from damage.

The peptides of the present invention exhibit skin whitening activity by inhibiting melanin synthesis in melanocytes and inhibiting melanin body migration. Therefore, the peptide of the present invention can be used as an active ingredient in a medicament for treating or preventing hyperpigmentation diseases caused by excessive deposition of melanin bodies, or as an active ingredient in a cosmetic for skin whitening.

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

This invention discloses the use of ONO-2952 or a pharmaceutically acceptable salt thereof in the preparation of drugs / cosmetics for treating and / or preventing hyperpigmentation disorders, belonging to the field of pharmaceutical technology. ONO-2952 of this invention inhibits melanin synthesis induced by endogenous factors α-MSH, ACTH, and UVB radiation, thereby inhibiting melanin synthesis by suppressing the expression of key melanin synthesis proteins MITF and Tyrosinase in melanocytes. Therefore, ONO-2952 or a pharmaceutically acceptable salt thereof can be used in the preparation of drugs / cosmetics for treating and / or preventing hyperpigmentation disorders.

The present invention relates to a composition comprising plant extracts. The composition according to the present invention has a skin whitening effect by reducing the total amount of melanin and tyrosinase activity in melanocytes of the skin, promotes skin regeneration and increases skin elasticity or reduces skin wrinkles by promoting collagen synthesis and inhibiting collagenase activity in fibroblasts of the skin, has an anti-inflammatory effect or a skin soothing effect by inhibiting NO generation, increases the amount of moisture in the skin and has a moisturizing effect by promoting generation of hyaluronic acid in fibroblasts, and has an antioxidant effect by scavenging free radicals. In addition, since the composition of the present invention exhibits a broad antibacterial effect against various bacteria, the composition may be used as a cosmetic composition, a pharmaceutical composition, a skin external preparation, or a food composition.

The invention discloses a whitening composition as well as a preparation method and application thereof. The whitening composition is prepared from the following components: a tea leaf extract, a lavender flower extract and water, wherein the tea leaf extract, the lavender flower extract and the water are added into the whitening composition. The whitening composition can interact and synergistically improve the autophagy ability of cells, synergistically improve the phagocytosis of melanin in keratinocytes and the removal ability of skin metabolic wastes, can synergistically inhibit the generation of melanin and synergistically improve the expression of miR-137 genes in melanocytes, has a relatively high development prospect of cosmetics with whitening effects, and has a wide application prospect. Moreover, the composition is mild in property, easy to absorb and non-irritant, and can be widely applied to skin care cosmetics.

The invention discloses application of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor in preparation of a medicine for treating leucoderma, and belongs to the technical field of preparation of medicines for treating leucoderma. Through targeted inhibition of ACLY activity or specific knockout of ACLY in CD8 + T cells, abnormal activation of ACLY and secretion of killing effector molecules (Granzyme B, IFN-gamma, Perforin and the like) are inhibited, and infiltration of the CD8 + T cells to skin lesion parts is reduced, so that melanocytes are protected from immune injury, and the progress of vitiligo is blocked. The application is based on the abnormally high expression of ACLY in CD8 + T cells of vitiligo patients and the close association with disease activity, and a brand new targeted treatment thought and a medicine research and development direction are provided for vitiligo.

The present application relates to azapeptide compounds of formula (I) derived from melanocyte-stimulating hormone release-inhibiting factor-1. A method to obtain compounds of formula (I) is also described herein. The compounds of formula (I) have been shown to be suitable for the treatment of dopamine-related disorders of the central nervous system. These compounds showed enhanced potency as positive allosteric modulators of the dopamine D2 receptors in comparison with the melanocyte-stimulating hormone release- inhibiting factor-1 and, in general, do not exhibit meaningful cytotoxicity.

The invention relates to hair-blacking essence and a preparation method thereof. Screening a symbiotic bacterium metabolism extract with small molecule peptide metabolism regulation capability; by combining low-concentration azelaic acid and zinc lactate components, scalp grease oxidation and abnormal proliferation of propionibacterium are inhibited; the expression of IL-10 anti-inflammatory factors is induced, the expression of TNF-alpha and IL-6 is reduced, and the hair follicle microinflammation state is reduced; a Wnt / beta-catenin pathway activator is used for inducing the melanin stem cells to be in a static state; the FGF-2 and the EGF are combined in a micro-dose manner to promote the amplification into precursor cells; mITF regulation peptides and a small amount of trace copper ions are supplemented to induce directional differentiation into mature melanocytes; a microcapsule carrier system with a three-layer structure; the penetration efficiency is improved; antioxidative peptide rich in reduced glutathione, NAD and a promoting factor are used, so that melanocytes are protected from oxidative damage; a coenzyme Q10 type mitochondrial homeostasis regulator is introduced, so that the energy metabolism is improved, the cell aging is delayed, the targeting property is strong, and the effect is accurate.

A composition for promoting tyrosinase activity, which includes a peptide consisting of the amino acid sequence of General Formula 1 below: K—Y—R1-R2-R3-R4-R5-R6-R7-R8 (General Formula 1) is disclosed. In General Formula 1, R1 is arginine (R), lysine (K), or glutamine (Q); R2 is arginine (R) or glutamine (Q); R3, R4, and R5 are each arginine (R) or lysine (K); R6 is asparagine (N) or serine (S); and R7 and R8 are each lysine (K) or tyrosine (Y). The composition may promote melanogenesis in melanocytes to prevent, improve or treat hypomelanosis.

This invention discloses a skin-whitening composition that reduces aging melanocytes and its application, relating to the cosmetics field. The invention provides a composition that, by reducing aging melanocytes and decreasing SASP secretion, reduces melanin production and inhibits tyrosinase activity while maintaining healthy melanocytes, thus maintaining skin homeostasis while whitening the skin. This composition can be widely used in various skincare products to effectively achieve long-lasting whitening effects.

The invention discloses a natural spray for promoting blackening of white hair and growth of hair and a preparation method of the natural spray. The spray is prepared by compounding natural plant extracts of polygonum multiflorum, cacumen biotae, black sesame, fructus viticis, angelica sinensis, ginger, ligusticum wallichii, liquorice and the like, and clove or / and cinnamon extract is creatively adopted as a natural preservative flavor enhancer. Through a multi-target synergistic system of nourishing, blood activating and infiltration promoting and activating, anti-inflammation and stability maintaining, hair follicle melanocytes can be nourished from the source, white hair can be naturally turned into black, dormant hair follicles can be effectively activated, and hair growth is promoted. Preferably, ginseng and lucid ganoderma extracts can also be added to enhance the nourishing and stability maintaining effects. The invention aims to overcome the double defects in the prior art, and provides a multifunctional spray which is 100% purely natural and does not contain any chemically synthesized dye, oxidant, hormone, chemical preservative and harmful additive. The invention aims to realize natural blackening of white hair by gradually recovering melanin synthesis of hair follicles through exogenous nutrition supplement, and effectively promote hair growth and prevent hair loss by stimulating scalp microcirculation, resisting inflammation, relieving and directly activating hair papilla cells. The invention finally provides a daily care product which integrates blackening, hair growth and maintenance, is convenient to use (washing-free after spraying) and does not need to be cleaned. All the components are natural, safe and non-irritant, and the shampoo adopts a washing-free spray design, is convenient to use and is suitable for all hair qualities.

The invention relates to the field of cosmetics, in particular to a compound and application thereof. The inventor creatively discovers that the compound with the structure shown in the formula I has the effect of inhibiting melanocytes and tyrosinase, and proves that the compound has new application in whitening and has application in preparation of whitening products. Experiments show. The compound with the structure shown in the formula I is superior to the traditional capsaicin with a whitening effect in the inhibition effect on melanocytes and tyrosinase.

The peptides of the invention have a sequence with at least 85% of identity with a sequence SEQ ID NO: 1 or 2. These peptides regulate melanocyte activity in terms of proliferation and production of melanin. Therefore, they are useful in the treatment of melanomas but also of cosmetic cutaneous hyper or hypopigmentation.

The purpose of the present invention is to suppress the effect of ultraviolet light on melanocytes. Upon performance of gene expression analysis with a focus on the olfactory receptor OR2L13 expressed by melanocytes, it was discovered that addition of (−)-carvone, a ligand of OR2L13, increased the expression of genes related to suppression of active oxygen, suppression of the production of inflammatory cytokines or chemokines, suppression of senescence, and / or degradation of abnormal proteins. As a result of said discovery, the present invention provides an inhibitor of the effects of ultraviolet light on melanocytes that includes (−)-carvone.

The present disclosure relates to biaryl aminoguanidine derivatives of Formula II or a pharmaceutically acceptable salt thereof and processes for their preparation. The present disclosure also relates to the use of such biaryl aminoguanidine derivatives for the treatment of diseases involving the melanocortin receptor or related systems, such as proopiomelanocortin-related diseases.

Provided herein are compositions for skin lightening and for the prevention and / or treatment of skin pigmentation disorders. Also provided herein are methods and uses for preventing and / or treating skin pigmentation disorders, for inhibiting melanin production in epidermal melanocytes and / or promoting melanin degradation in dermal fibroblasts, and non-therapeutic methods for lightening complexion.

The application discloses a white hair to black hair essence and a preparation method thereof. The white hair to black hair essence is prepared from selected raw materials, such as water dropwort leaf / stem extract, oxyhematin, radix polygoni multiflori, panax notoginseng and the like, and has good effects on activating hair follicles, enhancing the activity of melanocytes in the hair follicles and promoting melanin production. Volunteer tests prove that with the growth of new black hair and the shedding of aging white hair, the black hair gradually increases and the white hair gradually decreases by long-term use of the white hair to black hair essence, and the sensory effect of 'white hair to black hair' is achieved.

It has been discovered that differential methylation in DNA can be used to distinguish between malignant and non-malignant skin lesions. Seven genes, 3 that are hypermethylated in melanoma, 1 that is hypermethylated in melanocytes and remains methylated in melanoma, and 3 that are hypermethylated in all tissues are provided as biomarkers. The panel demonstrates a 93% sensitivity, 97% specificity and an AUC of 95% in distinguishing between melanoma and benign lesions. Thus provided herein are melanoma biomarkers and methods of detecting them and using them to diagnose and guide treatment of subjects with the same, and monitor melanoma tumor dynamics during and after treatment.

The invention relates to the technical field of cosmetics, in particular to a mark fading and repairing composition as well as a preparation method and application thereof. The invention relates to a mark fading and repairing composition which comprises the following components in percentage by weight: 0.1%-5% of dragon's blood extract, 0.01%-0.5% of keratinase and 1%-5% of nicotinamide, the preparation method comprises the following steps: preparing the eutectic solvent; performing ultrasonic-assisted extraction; separation and post-treatment; the invention has the following beneficial effects: the resina draconis extract can inhibit continuous pigmentation caused by acne inflammation residue, promote healing of skin minimal wounds and reduce dermis layer injury of acne mark parts; keratinase specifically hydrolyzes stratum corneum aged keratin, cutin metabolism of acne mark parts is accelerated, and accumulation of pigments in stratum corneum is avoided; nicotinamide inhibits melanocytes from transferring melanin to keratinocytes; through the synergistic effect of the three components, a closed-loop printing fading mechanism of anti-inflammatory repair-keratin metabolism-pigment inhibition is formed, the printing fading effect is more comprehensive and more efficient, and skin repair and barrier protection can be both considered.

The invention discloses a composition with a whitening effect. The composition is prepared from the following components in parts by mass: 47 to 51 parts of grape seed oil, 47 to 51 parts of pomegranate seed oil, 0.5 to 0.8 part of 4-butylresorcinol, 0.2 to 0.6 part of VC-IP (Vitamin C-IP) and 0.1 to 10 parts of isorhamnetin-3-O-neohesperidin. The invention also discloses a preparation method of the composition. The invention also discloses an essence oil containing the composition. The invention also discloses a face cream containing the composition. The invention also discloses application of the composition in preparation of cosmetics for skin whitening, spot fading and skin yellowing reduction. The composition provided by the invention establishes a multi-target synergistic pathway: 1, a blackness removal pathway for reducing the activation of oxidative stress such as ultraviolet rays on melanocytes; and 2, a jaundice removal pathway: inhibiting lipid peroxidation and promoting lipofuscin removal.

The invention discloses a preparation method of bionic vesicles simultaneously targeting skin keratinocytes and fibroblasts and anti-aging application of the bionic vesicles, and belongs to the technical field of pharmaceutical preparations and cosmetics. According to the invention, the surface of liposome is modified with melanin cell membrane protein by using a microfluidic technology, and the membrane characteristics of melanin cells are integrated to a vesicle carrier through a biomimetic membrane structure, so that the effect of simultaneously targeting keratinocytes and fibroblasts is realized. The melanin cell membrane protein-derived bionic vesicles prepared by the invention can effectively target skin keratinocytes and fibroblasts, and the specific uptake of the vesicles by the cells is enhanced. After fisetin is loaded, the accumulation of fisetin in skin keratinocytes and fibroblasts can be remarkably improved, so that senescent cells are more effectively removed. Therefore, the bionic vesicles simultaneously targeting the skin keratinocytes and the fibroblasts, which are constructed by the invention, have great application prospects in the field of skin aging treatment.

The invention provides new application of an ATOX1 gene and ATOX1 protein, and belongs to the technical field of treatment of vitiligo diseases. The ATOX1 gene serving as a key gene of copper metabolism is disclosed for the first time, and melanin synthesis is promoted by activating the melanocyte copper metabolism process, so that the effect of resisting leucoderma is achieved. The ATOX1 gene and / or the ATOX1 protein can be used as a key biomarker in the vitiligo morbidity process, and a new target and a new molecular basis are provided for vitiligo research.

Hypomelanosis of Ito is a clinical term for patients with mosaic syndromes characterized by skin hypopigmentation and developmental disorders. The genetic causes of these rare diseases remain largely unclear. Here, we report that GNA13 is a new gene that causes Hypomelanosis of Ito. We identified an identical mutation in this gene in four unrelated patients exhibiting pigmentary mosaicism. In depth functional investigations revealed that this is an activatory mutation that alters the cytoskeleton and morphology of melanocytes via a hyperactivation of the RHOA / ROCK signalling pathway. Our results also indicate that this pathology does not necessarily originate from a decreased production of melanin, but can originate from a defect in melanosome transfer to keratinocytes due to cell shape alterations. Thus, our findings suggest for the first time a mechanism by which the clinical symptoms of patients with Hypomelanosis of Ito appear, and pave the path for new therapeutic approaches. Altogether, the present invention relates to a method for treating a patient suffering from hypomelanosis of Ito by administering a ROCK inhibitor and / or RHOA inhibitor.

The invention relates to the field of fluorescent probes and biological detection, and discloses a tyrosinase and hydrogen sulfide double-target fluorescent probe as well as a preparation method and application thereof. The fluorescent probe provided by the invention is characterized in that the fluorescence of the fluorescent probe is extremely weak, but when tyrosinase and hydrogen sulfide coexist, a specific chemical reaction can occur, the fluorescence effect is obviously started, and strong green fluorescence is generated at 517nm, so that the detection on the activity of tyrosinase and the content of hydrogen sulfide is realized. The probe not only can be used for detecting content changes of tyrosinase and hydrogen sulfide in human primary melanocytes, but also can be used for imaging analysis of human melanoma tissue slices, and a new tool is provided for early diagnosis and histological research of melanoma.

The present invention relates to a multimodal non-invasive in vivo system and related method for the characterization of the tissue microenvironment. The system comprises: a multispectral imaging (MSI) camera for superficial spectral screening; a multispectral optoacoustic tomography (MSOT) module for dynamic vascular and perfusion analysis; a Mueller Matrix Polarimetry (MMP) module for extracellular matrix anisotropy assessment; a Raman spectroscopy module for molecular fingerprinting of fibroblast-associated proteins; an optical coherence tomography (OCT) module for morphological and stratigraphic evaluation; an optional Elastic Scattering Spectroscopy (ESS) module for subcellular scattering biomarkers; and a diachronic analysis module for longitudinal monitoring. Data are integrated by an artificial intelligence processing unit to generate quantitative biomarkers of vascularization, extracellular matrix features, immune activity (Langerhans cells) and fibroblast phenotype, distinguishing physiological myofibroblasts from CAF. The invention enables non-nvasive, biopsy-free evaluation of scars, melanocytic lesions, tumor stroma, wound healing and surgical site monitoring.

Vitiligo is a complex auto-immune skin disease resulting in melanocytes loss and skin depigmentation. Following-up on their previous work identifying mitochondrial DNA (mtDNA) in skin biopsies from some vitiligo patients, the inventors demonstrate here that melanocytes from non-lesional skin present elevated numbers of mtDNA variants associated with mtDNA release and can be classified as function of their number of mtDNA variants in low-variant (LV) and high-variant (HV) load. Vitiligo HV melanocytes display increased ROS production, reduced antioxidant capacity, elevated mitochondrial function and mtDNA release as compared to Vitiligo LV and healthy melanocytes. Sensing of mtDNA by the cGAS-STING pathway results in pro-inflammatory cytokine and chemokines production promoting the recruitment of cytotoxic CD8+ T cells. This cascade of events can be blocked with TBK1 inhibitors suggesting new therapeutic approaches for sub-population of vitiligo patients displaying HV mtDNA phenotype. The present invention relates to method for the treatment of vitiligo in a subject in need thereof comprising a step of administrating to the subject a therapeutically effective amount of TANK-binding kinase 1 (TBK1) inhibitor.

Provided is a use of α-MSH or a promoter thereof in liver cancer; specifically, provided is a use of α-MSH, an analog thereof or a promoter thereof for preparing a pharmaceutical composition or preparation for: (i) inhibiting the growth of liver cancer cells, and / or (ii) treating liver cancer. The pharmaceutical composition or preparation can induce apoptosis of liver cancer cells, reducing the number of liver cancer cells and thus achieving an anti-tumor effect.